vs
亨斯迈（HUN）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
亨斯迈的季度营收约是Medpace Holdings, Inc.的1.9倍（$1.4B vs $708.5M），Medpace Holdings, Inc.净利率更高（19.1% vs -7.1%，领先26.2%），Medpace Holdings, Inc.同比增速更快（32.0% vs -6.7%），Medpace Holdings, Inc.自由现金流更多（$188.1M vs $19.0M），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs -4.0%）
亨斯迈公司是总部位于美国得克萨斯州伍德兰兹的全球化化工巨头，面向消费端与工业客户生产、销售各类化工产品，主营聚氨酯、高性能材料及胶粘剂，客户覆盖宝马、通用电气、雪佛龙、宝洁、联合利华等知名品牌。目前公司在全球25个国家设有60余处生产、研发及运营基地，员工约7000人。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
HUN vs MEDP — 直观对比
营收规模更大
HUN
是对方的1.9倍
$708.5M
营收增速更快
MEDP
高出38.7%
-6.7%
净利率更高
MEDP
高出26.2%
-7.1%
自由现金流更多
MEDP
多$169.1M
$19.0M
两年增速更快
MEDP
近两年复合增速
-4.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $708.5M |
| 净利润 | $-96.0M | $135.1M |
| 毛利率 | 12.1% | — |
| 营业利润率 | -4.4% | 21.6% |
| 净利率 | -7.1% | 19.1% |
| 营收同比 | -6.7% | 32.0% |
| 净利润同比 | 31.9% | 15.5% |
| 每股收益（稀释后） | $-0.56 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HUNMEDP
| Q4 25 | $1.4B | $708.5M | ||
| Q3 25 | $1.5B | $659.9M | ||
| Q2 25 | $1.5B | $603.3M | ||
| Q1 25 | $1.4B | $558.6M | ||
| Q4 24 | $1.5B | $536.6M | ||
| Q3 24 | $1.5B | $533.3M | ||
| Q2 24 | $1.6B | $528.1M | ||
| Q1 24 | $1.5B | $511.0M |
净利润HUNMEDP
| Q4 25 | $-96.0M | $135.1M | ||
| Q3 25 | $-25.0M | $111.1M | ||
| Q2 25 | $-158.0M | $90.3M | ||
| Q1 25 | $-5.0M | $114.6M | ||
| Q4 24 | $-141.0M | $117.0M | ||
| Q3 24 | $-33.0M | $96.4M | ||
| Q2 24 | $22.0M | $88.4M | ||
| Q1 24 | $-37.0M | $102.6M |
毛利率HUNMEDP
| Q4 25 | 12.1% | — | ||
| Q3 25 | 14.0% | — | ||
| Q2 25 | 12.5% | — | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 12.9% | — | ||
| Q3 24 | 15.2% | — | ||
| Q2 24 | 15.4% | — | ||
| Q1 24 | 13.7% | — |
营业利润率HUNMEDP
| Q4 25 | -4.4% | 21.6% | ||
| Q3 25 | 0.4% | 21.5% | ||
| Q2 25 | -8.2% | 20.9% | ||
| Q1 25 | 3.0% | 20.3% | ||
| Q4 24 | -4.3% | 23.4% | ||
| Q3 24 | 2.7% | 21.1% | ||
| Q2 24 | 2.2% | 19.9% | ||
| Q1 24 | -2.6% | 20.4% |
净利率HUNMEDP
| Q4 25 | -7.1% | 19.1% | ||
| Q3 25 | -1.7% | 16.8% | ||
| Q2 25 | -10.8% | 15.0% | ||
| Q1 25 | -0.4% | 20.5% | ||
| Q4 24 | -9.7% | 21.8% | ||
| Q3 24 | -2.1% | 18.1% | ||
| Q2 24 | 1.4% | 16.7% | ||
| Q1 24 | -2.5% | 20.1% |
每股收益（稀释后）HUNMEDP
| Q4 25 | $-0.56 | $4.65 | ||
| Q3 25 | $-0.14 | $3.86 | ||
| Q2 25 | $-0.92 | $3.10 | ||
| Q1 25 | $-0.03 | $3.67 | ||
| Q4 24 | $-0.82 | $3.67 | ||
| Q3 24 | $-0.19 | $3.01 | ||
| Q2 24 | $0.13 | $2.75 | ||
| Q1 24 | $-0.22 | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.0M | $497.0M |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $2.8B | $459.1M |
| 总资产 | $7.0B | $2.0B |
| 负债/权益比越低杠杆越低 | 0.73× | — |
8季度趋势，按日历期对齐
现金及短期投资HUNMEDP
| Q4 25 | $429.0M | $497.0M | ||
| Q3 25 | $468.0M | $285.4M | ||
| Q2 25 | $399.0M | $46.3M | ||
| Q1 25 | $334.0M | $441.4M | ||
| Q4 24 | $340.0M | $669.4M | ||
| Q3 24 | $330.0M | $656.9M | ||
| Q2 24 | $335.0M | $510.9M | ||
| Q1 24 | $552.0M | $407.0M |
总债务HUNMEDP
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | $2.1B | — |
股东权益HUNMEDP
| Q4 25 | $2.8B | $459.1M | ||
| Q3 25 | $2.8B | $293.6M | ||
| Q2 25 | $2.8B | $172.4M | ||
| Q1 25 | $3.0B | $593.6M | ||
| Q4 24 | $3.0B | $825.5M | ||
| Q3 24 | $3.1B | $881.4M | ||
| Q2 24 | $3.1B | $763.6M | ||
| Q1 24 | $3.2B | $671.5M |
总资产HUNMEDP
| Q4 25 | $7.0B | $2.0B | ||
| Q3 25 | $7.1B | $1.8B | ||
| Q2 25 | $7.1B | $1.6B | ||
| Q1 25 | $7.2B | $1.9B | ||
| Q4 24 | $7.1B | $2.1B | ||
| Q3 24 | $7.3B | $2.1B | ||
| Q2 24 | $7.3B | $1.9B | ||
| Q1 24 | $7.6B | $1.8B |
负债/权益比HUNMEDP
| Q4 25 | 0.73× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.62× | — | ||
| Q3 24 | 0.60× | — | ||
| Q2 24 | 0.62× | — | ||
| Q1 24 | 0.65× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $76.0M | $192.7M |
| 自由现金流经营现金流 - 资本支出 | $19.0M | $188.1M |
| 自由现金流率自由现金流/营收 | 1.4% | 26.6% |
| 资本支出强度资本支出/营收 | 4.2% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 1.43× |
| 过去12个月自由现金流最近4个季度 | $116.0M | $681.9M |
8季度趋势，按日历期对齐
经营现金流HUNMEDP
| Q4 25 | $76.0M | $192.7M | ||
| Q3 25 | $196.0M | $246.2M | ||
| Q2 25 | $91.0M | $148.5M | ||
| Q1 25 | $-74.0M | $125.8M | ||
| Q4 24 | $153.0M | $190.7M | ||
| Q3 24 | $129.0M | $149.1M | ||
| Q2 24 | $46.0M | $116.4M | ||
| Q1 24 | $-65.0M | $152.7M |
自由现金流HUNMEDP
| Q4 25 | $19.0M | $188.1M | ||
| Q3 25 | $153.0M | $235.5M | ||
| Q2 25 | $54.0M | $142.4M | ||
| Q1 25 | $-110.0M | $115.8M | ||
| Q4 24 | $102.0M | $183.0M | ||
| Q3 24 | $88.0M | $138.5M | ||
| Q2 24 | $-4.0M | $103.5M | ||
| Q1 24 | $-107.0M | $147.2M |
自由现金流率HUNMEDP
| Q4 25 | 1.4% | 26.6% | ||
| Q3 25 | 10.5% | 35.7% | ||
| Q2 25 | 3.7% | 23.6% | ||
| Q1 25 | -7.8% | 20.7% | ||
| Q4 24 | 7.0% | 34.1% | ||
| Q3 24 | 5.7% | 26.0% | ||
| Q2 24 | -0.3% | 19.6% | ||
| Q1 24 | -7.3% | 28.8% |
资本支出强度HUNMEDP
| Q4 25 | 4.2% | 0.6% | ||
| Q3 25 | 2.9% | 1.6% | ||
| Q2 25 | 2.5% | 1.0% | ||
| Q1 25 | 2.6% | 1.8% | ||
| Q4 24 | 3.5% | 1.4% | ||
| Q3 24 | 2.7% | 2.0% | ||
| Q2 24 | 3.2% | 2.4% | ||
| Q1 24 | 2.9% | 1.1% |
现金转化率HUNMEDP
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | 2.09× | 1.32× | ||
| Q1 24 | — | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HUN
| Diversified | $897.0M | 66% |
| Specialty | $231.0M | 17% |
| Performance Products | $113.0M | 8% |
| Advanced Materials | $61.0M | 5% |
| Related Party Customers | $19.0M | 1% |
| Other | $12.0M | 1% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
